Panacos Pharmaceuticals (OTCPK:PANC) - Stock Price, News & Analysis

PANC Stock Overview

A development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. More details

PANC fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Latest financial reports are more than a year old

Does not have a meaningful market cap ($53)

Panacos Pharmaceuticals, Inc. Competitors

DermTech

OTCPK:DMTK.Q

US$35.0

ObsEva

OTCPK:OBSE.F

US$11.7k

eFFECTOR Therapeutics

OTCPK:EFTR

US$940.0

MJ Holdings

OTCPK:MJNE

US$58.0

Price History & Performance

Summary of all time highs, changes and price drops for Panacos Pharmaceuticals
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.0085
52 Week Low	US$0.000001
Beta	0
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-99.00%
5 Year Change	0%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	PANC	US Biotechs	US Market
7D	0%	2.5%	1.0%
1Y	n/a	15.6%	31.4%

Return vs Industry: Insufficient data to determine how PANC performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how PANC performed against the US Market.

Price Volatility

Is PANC's price volatile compared to industry and market?
PANC volatility
PANC Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stable Share Price: PANC's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine PANC's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1999	n/a	n/a	n/a

Panacos Pharmaceuticals, Inc., a development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The company’s discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion. Its product pipeline includes second- and third-generation programs in HIV maturation inhibition.

Panacos Pharmaceuticals, Inc. Fundamentals Summary

How do Panacos Pharmaceuticals's earnings and revenue compare to its market cap?
PANC fundamental statistics
Market cap	US$53.00
Earnings (TTM)	-US$35.75m
Revenue (TTM)	US$99.00k

0.0x

P/S Ratio

0.0x

P/E Ratio

Is PANC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PANC income statement (TTM)
Revenue	US$99.00k
Cost of Revenue	US$0
Gross Profit	US$99.00k
Other Expenses	US$35.85m
Earnings	-US$35.75m

Last Reported Earnings

Sep 30, 2008

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did PANC perform over the long term?

See historical performance and comparison